(Q38811689)

English

The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice

scientific article published on 15 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice (English)

1 reference

Europe PubMed Central

6 September 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Nicholas D Brunn

1

1 reference

Europe PubMed Central

6 September 2017

Smita Mauze

2

1 reference

Europe PubMed Central

6 September 2017

Danling Gu

3

1 reference

Europe PubMed Central

6 September 2017

Derek Wiswell

4

1 reference

Europe PubMed Central

6 September 2017

Roanna Ueda

5

1 reference

Europe PubMed Central

6 September 2017

Douglas Hodges

6

1 reference

Europe PubMed Central

6 September 2017

Amy M Beebe

7

1 reference

Europe PubMed Central

6 September 2017

Shuli Zhang

8

1 reference

Europe PubMed Central

6 September 2017

Enrique Escandón

9

1 reference

Europe PubMed Central

6 September 2017

language of work or name

0 references

publication date

15 December 2015

1 reference

Europe PubMed Central

6 September 2017

Journal of Pharmacology and Experimental Therapeutics

1 reference

Europe PubMed Central

6 September 2017

356

1 reference

Europe PubMed Central

6 September 2017

3

1 reference

Europe PubMed Central

6 September 2017

574-586

1 reference

Europe PubMed Central

6 September 2017

Anaphylactic shock after retreatment with OKT3 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Immune response to biologic scaffold materials

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Strategies and challenges for the next generation of therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Minimizing the immunogenicity of protein therapeutics

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Clinical targeting of the TNF and TNFR superfamilies

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

FcγRIIb on liver sinusoidal endothelium clears small immune complexes

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

An efficient method to isolate and culture mouse Kupffer cells

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Intratumoral immunization: a new paradigm for cancer therapy

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Immunostimulatory monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Immune modulation in cancer with antibodies

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Antibody-based therapeutics to watch in 2011.

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Modulation of GITR for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Scientific and regulatory considerations on the immunogenicity of biologics

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.229864

21 January 2018

Identifiers

10.1124/JPET.115.229864

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

6 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38811689&oldid=2144474114"